Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05121662 · ClinicalTrials.gov registry record
COVID-19 Vaccine Biomarker Study in Multiple Sclerosis
A clinical trial, sponsored by Columbia University.
- Completed
- Registry status
- 154
- Enrollment target
NCT05121662 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 154 participants.
The verdict
NCT05121662 has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 154 participants
- Enrollment target
Study Summary
SARS CoV-2 is the virus responsible for the pandemic COVID-19, which has resulted in nearly five million deaths worldwide since its spread in the beginning of 2020. In the United States, there are now two emergency use authorized vaccines that make use of messenger ribonucleic acid (mRNA) based technology that are highly effective for preventing COVID. However, because multiple sclerosis is an autoimmune condition, many individuals with multiple sclerosis take medicines that affect the immune system. The investigators are not sure whether individuals on certain MS medications, including medications that lower a type of immune cell called B lymphocytes, will form as robust of a response to the vaccines. In this study, the investigators will be gathering more information about effectiveness of these vaccines and bloodwork that looks at antibodies and other markers of vaccine response and by asking patients about COVID-19 infections.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2021-07-29 |
| Est. Completion | 2025-02-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05121662
The ClinicalTrials.gov registry entry for NCT05121662 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05121662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05121662 about?
NCT05121662 is a clinical study titled "COVID-19 Vaccine Biomarker Study in Multiple Sclerosis". SARS CoV-2 is the virus responsible for the pandemic COVID-19, which has resulted in nearly five million deaths worldwide since its spread in the beginning of 2020. In the United States, there are now two emergency use authorized vaccines that make use of messenger ribonucleic acid (mRNA) based tech...
What is the current status of trial NCT05121662?
This trial is currently completed. The enrollment target is 154 participants. The study started on 2021-07-29. Estimated completion is 2025-02-13.
Who is sponsoring clinical trial NCT05121662?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.